Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallium cation, primarily in its trivalent form (Ga3+), is a therapeutic agent that mimics ferric iron (Fe3+) due to its chemical similarity. It exerts its effects by interfering with iron metabolism, a vital process for both tumor growth and bacterial proliferation. The cation is redox inactive in typical physiological environments. Its mechanism involves competing with Fe3+ for binding to siderophores and transferrin, thereby disrupting cellular iron acquisition. It also interacts with iron-dependent enzymes like ribonucleotide reductase, leading to reduced dNTP pools and inhibition of DNA synthesis. Furthermore, Ga3+ can target bacterial iron uptake systems, such as the Pseudomonas quinolone signal (PQS) complexes, by displacing Fe3+ from these chelates. Gallium-based therapies, such as intravenous gallium nitrate, have shown clinical activity in lymphomas and bladder cancer, and formulations like gallium maltolate are being investigated for oral administration and antibacterial applications against pathogens like Pseudomonas aeruginosa.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gallium cation.